European Cancer Congress 2015: The Role of PD-1 Therapeutics in the Management of Patients with Metastatic Melanoma
This CME activity will focus on the essential sessions and new and emerging clinical data presented at the European Cancer Congress (ECC) 2015 annual meeting pertaining to metastatic melanoma and the role of PD-1 therapies. Because of the innate molecular heterogeneity of the disease, managing the metastatic melanoma patient and isolating the most beneficial targeted therapies has proven difficult. This notion is reflected in the poor long-term survival rates of patients in this therapeutic area. The most effective ways to implement recent clinical advancements and best utilize emerging and existing PD-1 therapies in everyday practice will be discussed throughout the duration of this program. With the information provided, learners will be able to better treat and manage their metastatic melanoma patients and improve outcomes.
Oncologists, surgical/radiation oncologists, dermatologists, and other healthcare professionals responsible for the treatment of patients with Melanoma.
Upon completion of this activity, participants will be able to:
- Review the recently released data for PD-1 therapies in the treatment of melanoma.
Analyze strategies to apply novel PD-1 specific treatments to the care of patients with melanoma
Jeffrey S. Weber, MD, PhD
Michael Postow, MD
Mario Sznol, MD
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Relationship Identified With:
Jeffrey S. Weber, MD
Consultant/Advisor: Amgen Inc.; AstraZeneca; Bristol-Myers Squibb Company; Genentech, Inc.; GlaxoSmithKline;Merck & Co., Inc.; Novartis AG;
Grant/Research Support: Amgen Inc.; AstraZeneca; Bristol-Myers Squibb Company; Genentech, Inc.; GlaxoSmithKline; Merck & Co., Inc.; Novartis AG
Michael Postow, MD
Consultant/Advisor: Bristol-Myers Squibb Company;Caladrius
Grant/Research Support: Bristol-Myers Squibb Company
Mario Sznol, MD
Consultant/Advisor: Astellas Pharma US, Inc.; AstraZeneca; Bristol-Myers Squibb Company; Eli and Lily Company;Genentech, Inc.; Immune Design; Immunova LLC; Kyowa Hakko Kirin Pharma Inc.; Merus Labs Inc.; Nektar; Novartis AG; Pfizer, Inc.; Prometheus Laboratories Inc.; The Pierre Fabre Group
Non-faculty: Sandy Breslow; Alison Kemp; Bernard Abrams, MD, Timothy Hayes, MD, PhD; Kristen Scollon; Emma Gilmartin and Nicole Brestowski hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
This activity has been supported by an independent educational grant from Bristol-Myers Squibb Company.
Co-provided by the Elsevier Office of Continuing Medical Education and AcademicCME.
Course Open Date: Janyuary 12, 2016 | Course Expiration Date: January 11, 2017
CME Credit (Physician)
The Elsevier Office of Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME Inquiries/Special Needs
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, AcademicCME, and Bristol-Myers Squibb Company do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 Non-physician